7 Sep 2018 16:10
7 September 2018
Issue of Equity
Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 196,215 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under The 2015 Clinigen Group Sharesave Plan and corresponding 2015 CSOP Matching Scheme and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 13 September 2018.
At admission the issued share capital of the Group will consist of 122,482,298 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 122,482,298. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Martin Abell, Group Chief Financial Officer | |
Matt Parrish, Head of Investor Relations | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com